This session will focus on an emerging approach to R&D using specific examples for public-private partnerships in chronic obstructive pulmonary disease and oncology. The role of biomarkers and patient-reported outcomes in research and development of new medicines, the current regulatory environment for biomarker and endpoint qualification, and key success factors for public-private partnerships will be discussed.

Learning Objectives:
Describe the role of biomarkers in R&D of new medicines
Discuss the current regulatory environment for biomarkers and PRO qualifications
Discuss the use of health care web-based registers for clinical research Identify key success factors for public-private partnerships using an example of COPD and oncology.